Computational prediction and experimental assessment of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from neutral endopeptidase

被引:7
作者
Zhang, Jingbo [1 ]
Jia, Zhengcai [2 ]
Lin, Zhihua [3 ]
Li, Jingyi [2 ]
Fu, Xiaolan [2 ]
Huang, Yunjian [1 ]
Zhao, Jinghong [1 ]
Nie, Ling [1 ]
Hou, Weiping [1 ]
Yuan, Fahuan [1 ]
Wu, Yuzhang [2 ]
机构
[1] Third Mil Med Univ, Xinqiao Hosp, Dept Nephrol, Chongqing 400037, Peoples R China
[2] Third Mil Med Univ, Inst Immunol PLA, Chongqing 400037, Peoples R China
[3] Chongqing Inst Technol, Coll Bioengn, Chongqing 400050, Peoples R China
基金
美国国家科学基金会;
关键词
Neutral endopeptidase; Membranous nephropathy; Antigen; Cytotoxic T cell; Computer epitope predicting; ACTIVE HEYMANN NEPHRITIS; ANTENATAL MEMBRANOUS GLOMERULONEPHRITIS; NEPHRITOGENIC ANTIBODIES; TARGET ANTIGENS; IDENTIFICATION; PEPTIDE; MEGALIN; NEPHROPATHY; DISEASE; BINDING;
D O I
10.1007/s12026-012-8330-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Neutral endopeptidase (NEP) is the first target antigen identified on podocytes in human membranous nephropathy (MN). Cytotoxic T lymphocytes (CTLs) are considered essential for glomerular destruction in MN model. The aim of this study was to show that the CTL epitopes of NEP could be used to design more effective and better tolerated therapies. The CTL epitopes of NEP were screened using the long-distance prediction system SYFPEITHI and the Bioinformatics and Molecular Analysis Section of the MHC Peptide Binding Predictions program. Peptides were synthesized and immunoreactivity was assessed by peptide-MHC-binding affinity assay, cytotoxicity assay and HLA-A2.1/Kb transgenic mice immunization. Five candidates were identified according to the high scores generated by the computer predicting system. Peptide NEP375-383 (FIMDLVSSL), which up-regulated HLA-A2.1 molecular expression, showed a high affinity to HLA-A2.1, whereas NEP268-276, NEP297--305 and NEP492-500 (QLALEMNKV, MLLYNKMRL and KLNNEYLEL) showed a moderate affinity and NEP559-567 (ILQPPFFSA) only had a low affinity. Cytotoxicity assay further showed that NEP268-276 and NEP375-383 could induce NEP-specific CTL responses in vitro. Unexpectedly, we found that a single CTL epitope, NEP375-383, could induce proteinuria and glomerular injury in HLA-A2.1/K-b transgenic mice in vivo. HLA-A*0201-restricted CTL epitope NEP375-383 can serve as a potential candidate for designing MN vaccine.
引用
收藏
页码:231 / 239
页数:9
相关论文
共 38 条
[1]  
Correale P, 1998, J IMMUNOL, V161, P3186
[2]   Antenatal membranous glomerulonephritis with vascular injury induced by anti-neutral endopeptidase antibodies: Toward new concepts in the pathogenesis of glomerular diseases [J].
Debiec, H ;
Guigonis, V ;
Mougenot, B ;
Haymann, JP ;
Bensman, A ;
Deschenes, G ;
Ronco, PM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (06) :S27-S32
[3]   Brief report - Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies [J].
Debiec, H ;
Guigonis, V ;
Mougenot, B ;
Decobert, F ;
Haymann, J ;
Bensman, A ;
Deschenes, G ;
Ronco, PM .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (26) :2053-2060
[4]  
ENGELHARD VH, 1991, J IMMUNOL, V146, P1226
[5]  
Evans MC, 2008, CURR OPIN DRUG DISC, V11, P233
[6]   DEFECTIVE PRESENTATION OF ENDOGENOUS ANTIGEN BY A CELL-LINE EXPRESSING CLASS-I MOLECULES [J].
HOSKEN, NA ;
BEVAN, MJ .
SCIENCE, 1990, 248 (4953) :367-370
[7]   Identification of Two Novel HLA-A*0201-Restricted CTL Epitopes Derived from MAGE-A4 [J].
Jia, Zheng-Cai ;
Ni, Bing ;
Huang, Ze-Min ;
Tian, Yi ;
Tang, Jun ;
Wang, Jing-Xue ;
Fu, Xiao-Lan ;
Wu, Yu-Zhang .
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2010,
[8]   ACTIVE HEYMANN NEPHRITIS IN COMPLEMENT COMPONENT C6 DEFICIENT RATS [J].
LEENAERTS, PL ;
HALL, BM ;
VANDAMME, BJ ;
DAHA, MR ;
VANRENTERGHEM, YF .
KIDNEY INTERNATIONAL, 1995, 47 (06) :1604-1614
[9]   Selection of peptides that bind to the HLA-A2.1 molecule by molecular modelling [J].
Lim, JS ;
Kim, S ;
Lee, HG ;
Lee, KY ;
Kwon, TJ ;
Kim, K .
MOLECULAR IMMUNOLOGY, 1996, 33 (02) :221-230
[10]  
Lundegaard Claus, 2010, Immunome Res, V6 Suppl 2, pS3, DOI 10.1186/1745-7580-6-S2-S3